RT Book, Section
A1 Scher, Howard I.
A1 Eastham, James A.
A2 Longo, Dan L.
SR Print(0)
ID 1135229749
T1 Benign and Malignant Diseases of the Prostate
T2 Harrison's Hematology and Oncology, 3e
YR 2016
FD 2016
PB McGraw-Hill Education
PP New York, NY
SN 9781259835834
LK hemonc.mhmedical.com/content.aspx?aid=1135229749
RD 2024/04/16
AB Benign  and  malignant  changes  in  the  prostate  increase  with  age.  Autopsies  of  men  in  the  eighth  decade  of  life  show  hyperplastic  changes  in  >90%  and  malignant  changes  in  >70%  of  individuals.  The  high  prevalence  of  these  diseases  among  the  elderly,  who  often  have  competing  causes  of  morbidity  and  mortality,  mandates  a  risk-adapted  approach  to  diagnosis  and  treatment.  This  can  be  achieved  by  considering  these  diseases  as  a  series  of  states.  Each  state  represents  a  distinct  clinical  milestone  for  which  therapy(ies)  may  be  recommended  based  on  current  symptoms,  the  risk  of  developing  symptoms,  or  death  from  disease  in  relation  to  death  from  other  causes  within  a  given  time  frame.  For  benign  proliferative  disorders,  symptoms  of  urinary  frequency,  infection,  and  potential  for  obstruction  are  weighed  against  the  side  effects  and  complications  of  medical  or  surgical  intervention.  For  prostate  malignancies,  the  risks  of  developing  the  disease,  symptoms,  or  death  from  cancer  are  balanced  against  the  morbidities  of  the  recommended  treatments  and  preexisting  comorbidities.